Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Identification of Celastramycin as a Novel Therapeutic Agent for Pulmonary Arterial Hypertension-High-throughput Screening of 5,562 Compounds.

Kurosawa R, Satoh K, Kikuchi N, Kikuchi H, Saigusa D, Al-Mamun EA, Siddique MAH, Omura J, Satoh T, Sunamura S, Nogi M, Numano K, Miyata S, Uruno A, Kano K, Matsumoto Y, Doi T, Aoki J, Oshima Y, Yamamoto M, Shimokawa H.

Circ Res. 2019 Jun 14. doi: 10.1161/CIRCRESAHA.119.315229. [Epub ahead of print]

PMID:
31195886
2.

Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease.

Kikuchi K, Saigusa D, Kanemitsu Y, Matsumoto Y, Thanai P, Suzuki N, Mise K, Yamaguchi H, Nakamura T, Asaji K, Mukawa C, Tsukamoto H, Sato T, Oikawa Y, Iwasaki T, Oe Y, Tsukimi T, Fukuda NN, Ho HJ, Nanto-Hara F, Ogura J, Saito R, Nagao S, Ohsaki Y, Shimada S, Suzuki T, Toyohara T, Mishima E, Shima H, Akiyama Y, Akiyama Y, Ichijo M, Matsuhashi T, Matsuo A, Ogata Y, Yang CC, Suzuki C, Breeggemann MC, Heymann J, Shimizu M, Ogawa S, Takahashi N, Suzuki T, Owada Y, Kure S, Mano N, Soga T, Wada T, Kopp JB, Fukuda S, Hozawa A, Yamamoto M, Ito S, Wada J, Tomioka Y, Abe T.

Nat Commun. 2019 Apr 23;10(1):1835. doi: 10.1038/s41467-019-09735-4.

3.

Generation and Characterization of Anti-phenyl Sulfate Monoclonal Antibodies and a Potential Use for Phenyl Sulfate Analysis in Human Blood.

Kanemitsu Y, Tsukamoto H, Matsumoto Y, Nozawa-Kumada K, Kondo Y, Abe T, Tomioka Y.

Biol Pharm Bull. 2018;41(8):1170-1177. doi: 10.1248/bpb.b17-00925.

4.

Detection of novel metabolite for roxadustat doping by global metabolomics.

Saigusa D, Suzuki N, Matsumoto Y, Umeda K, Tomioka Y, Koshiba S, Yamamoto M.

J Biochem. 2018 Jun 1;163(6):e1. doi: 10.1093/jb/mvy036. No abstract available.

PMID:
29771375
5.

Lipopolysaccharide (LPS)-binding protein stimulates CD14-dependent Toll-like receptor 4 internalization and LPS-induced TBK1-IKK¤Á-IRF3 axis activation.

Tsukamoto H, Takeuchi S, Kubota K, Kobayashi Y, Kozakai S, Ukai I, Shichiku A, Okubo M, Numasaki M, Kanemitsu Y, Matsumoto Y, Nochi T, Watanabe K, Aso H, Tomioka Y.

J Biol Chem. 2018 Jun 29;293(26):10186-10201. doi: 10.1074/jbc.M117.796631. Epub 2018 May 14.

PMID:
29760187
6.

The Disease-modifying Drug Candidate, SAK3 Improves Cognitive Impairment and Inhibits Amyloid beta Deposition in App Knock-in Mice.

Izumi H, Shinoda Y, Saito T, Saido TC, Sato K, Yabuki Y, Matsumoto Y, Kanemitsu Y, Tomioka Y, Abolhassani N, Nakabeppu Y, Fukunaga K.

Neuroscience. 2018 May 1;377:87-97. doi: 10.1016/j.neuroscience.2018.02.031. Epub 2018 Mar 3.

PMID:
29510211
7.

Detection of novel metabolite for Roxadustat doping by global metabolomics.

Saigusa D, Suzuki N, Matsumoto Y, Umeda K, Tomioka Y, Koshiba S, Yamamoto M.

J Biochem. 2018 Feb 9. doi: 10.1093/jb/mvy028. [Epub ahead of print]

PMID:
29438490
8.

Impact of the Oral Adsorbent AST-120 on Organ-Specific Accumulation of Uremic Toxins: LC-MS/MS and MS Imaging Techniques.

Sato E, Saigusa D, Mishima E, Uchida T, Miura D, Morikawa-Ichinose T, Kisu K, Sekimoto A, Saito R, Oe Y, Matsumoto Y, Tomioka Y, Mori T, Takahashi N, Sato H, Abe T, Niwa T, Ito S.

Toxins (Basel). 2017 Dec 28;10(1). pii: E19. doi: 10.3390/toxins10010019.

9.

Canagliflozin reduces plasma uremic toxins and alters the intestinal microbiota composition in a chronic kidney disease mouse model.

Mishima E, Fukuda S, Kanemitsu Y, Saigusa D, Mukawa C, Asaji K, Matsumoto Y, Tsukamoto H, Tachikawa T, Tsukimi T, Fukuda NN, Ho HJ, Kikuchi K, Suzuki C, Nanto F, Suzuki T, Ito S, Soga T, Tomioka Y, Abe T.

Am J Physiol Renal Physiol. 2018 Oct 1;315(4):F824-F833. doi: 10.1152/ajprenal.00314.2017. Epub 2017 Nov 22.

PMID:
29167170
10.

Simultaneous quantitative analysis of uremic toxins by LC-MS/MS with a reversed-phase/cation-exchange/anion-exchange tri-modal mixed-mode column.

Kanemitsu Y, Asaji K, Matsumoto Y, Tsukamoto H, Saigusa D, Mukawa C, Tachikawa T, Abe T, Tomioka Y.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Nov 15;1068-1069:1-8. doi: 10.1016/j.jchromb.2017.10.009. Epub 2017 Oct 5.

PMID:
29024911
11.

An inhibitory epitope of human Toll-like receptor 4 resides on leucine-rich repeat 13 and is recognized by a monoclonal antibody.

Tsukamoto H, Yamagata Y, Ukai I, Takeuchi S, Okubo M, Kobayashi Y, Kozakai S, Kubota K, Numasaki M, Kanemitsu Y, Matsumoto Y, Tomioka Y.

FEBS Lett. 2017 Sep;591(18):2953. doi: 10.1002/1873-3468.12837. No abstract available.

12.

An inhibitory epitope of human Toll-like receptor 4 resides on leucine-rich repeat 13 and is recognized by a monoclonal antibody.

Tsukamoto H, Yamagata Y, Ukai I, Takeuchi S, Okubo M, Kobayashi Y, Kozakai S, Kubota K, Numasaki M, Kanemitsu Y, Matsumoto Y, Tomioka Y.

FEBS Lett. 2017 Aug;591(16):2406-2416. doi: 10.1002/1873-3468.12768. Epub 2017 Aug 8. Erratum in: FEBS Lett. 2017 Sep;591(18):2953. Mumasaki, Muneo [corrected to Numasaki, Muneo].

13.

Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach.

Mishima E, Fukuda S, Mukawa C, Yuri A, Kanemitsu Y, Matsumoto Y, Akiyama Y, Fukuda NN, Tsukamoto H, Asaji K, Shima H, Kikuchi K, Suzuki C, Suzuki T, Tomioka Y, Soga T, Ito S, Abe T.

Kidney Int. 2017 Sep;92(3):634-645. doi: 10.1016/j.kint.2017.02.011. Epub 2017 Apr 8.

14.

Efficient N-Acyldopamine Synthesis.

Matsumoto Y, Ito A, Uesugi M, Kittaka A.

Chem Pharm Bull (Tokyo). 2016;64(7):935-40. doi: 10.1248/cpb.c16-00162.

15.

Design and synthesis of silicon-containing fatty acid amide derivatives as novel peroxisome proliferator-activated receptor (PPAR) agonists.

Kajita D, Nakamura M, Matsumoto Y, Ishikawa M, Hashimoto Y, Fujii S.

Bioorg Med Chem Lett. 2015 Aug 15;25(16):3350-4. doi: 10.1016/j.bmcl.2015.05.045. Epub 2015 May 27.

PMID:
26071639
16.

19-Norvitamin D analogs for breast cancer therapy.

Matsumoto Y, Kittaka A, Chen TC.

Can J Physiol Pharmacol. 2015 May;93(5):333-48. doi: 10.1139/cjpp-2014-0452. Epub 2015 Mar 6. Review.

PMID:
25918960
17.

Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.

Sakai T, Matsumoto Y, Ishikawa M, Sugita K, Hashimoto Y, Wakai N, Kitao A, Morishita E, Toyoshima C, Hayashi T, Akiyama T.

Bioorg Med Chem. 2015 Jan 15;23(2):328-39. doi: 10.1016/j.bmc.2014.11.027. Epub 2014 Dec 2.

PMID:
25515955
18.
19.

Design and synthesis of silicon-containing steroid sulfatase inhibitors possessing pro-estrogen antagonistic character.

Kajita D, Nakamura M, Matsumoto Y, Makishima M, Hashimoto Y.

Bioorg Med Chem. 2014 Apr 1;22(7):2244-52. doi: 10.1016/j.bmc.2014.02.025. Epub 2014 Feb 28.

PMID:
24630694
20.

Development of novel silicon-containing inverse agonists of retinoic acid receptor-related orphan receptors.

Toyama H, Nakamura M, Nakamura M, Matsumoto Y, Nakagomi M, Hashimoto Y.

Bioorg Med Chem. 2014 Mar 15;22(6):1948-59. doi: 10.1016/j.bmc.2014.01.023. Epub 2014 Feb 8.

PMID:
24559867

Supplemental Content

Loading ...
Support Center